Biotech 2012 - Managing Immunogenicity Risk in Biopharmaceuticals
Date2012-03-08
Deadline2012-03-08
VenuePalo Alto, USA - United States
KeywordsImmunogenicity Risk Regulations; Immunogenicity Risk training; biopharmaceutical regulations compliance; biopharmaceutical development programs; biopharmaceutical drug development
Topics/Call fo Papers
This Immunogenicity risk training Webinar will help you understand immunogenicity and analyzing risk factors to strategically develop biopharmaceuticals.
Why Should You Attend:
This presentation begins with an overview of the biological self versus non-self mechanism resulting in the anti-drug response of biopharmaceuticals. The next section describes how to differentiate the risk associated with internal attributes of the drug from the risk derived from external factors. That guideline in conjunction with the latest industry recommendations and regulatory guidelines provides a logical approach to the risk strategy.
Areas Covered in the seminar:
This presentation reviews the following important topics to understand immunogenicity and analyzing risk factors to strategically develop biopharmaceuticals:
- Self versus non-self.
- Risk factors associated with immunogenicity.
- Regulatory expectations on immunogenicity testing .
- How to use immunogenicity results from pre-clinical studies.
- Minimizing immunogenicity risk.
- Phase specific sampling plan.
- Case study and commercialization strategy.
Why Should You Attend:
This presentation begins with an overview of the biological self versus non-self mechanism resulting in the anti-drug response of biopharmaceuticals. The next section describes how to differentiate the risk associated with internal attributes of the drug from the risk derived from external factors. That guideline in conjunction with the latest industry recommendations and regulatory guidelines provides a logical approach to the risk strategy.
Areas Covered in the seminar:
This presentation reviews the following important topics to understand immunogenicity and analyzing risk factors to strategically develop biopharmaceuticals:
- Self versus non-self.
- Risk factors associated with immunogenicity.
- Regulatory expectations on immunogenicity testing .
- How to use immunogenicity results from pre-clinical studies.
- Minimizing immunogenicity risk.
- Phase specific sampling plan.
- Case study and commercialization strategy.
Other CFPs
- Accelerating Bioassay Transfer in a GMP Environment
- Live Webinar On 21 CFR Part 11 Add-On Inspections by the FDA By Compliance2go
- ISO14000: Environmental Management - Ins and Outs of Implementation and Understanding
- Life Cycle Validation of GMP Potency Bioassays
- Live Webinar On HOW TO MANAGE COMPLAINT FILES By Compliance2go
Last modified: 2011-12-08 20:14:09